Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist that works to inhibit bile acid synthesis. On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). The drug was also approved by the EMA on September 23, 2024. Elafibranor is an orally available peroxisome proliferator-activated receptor agonist that is used in combination with ursodeoxycholic acid to treat primary biliary cholangitis. Elafibranor therapy is associated with rare instances of worsening of liver enzymes during therapy but has not been convincingly linked to episodes of clinically apparent liver injury with jaundice. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Iqirvo and elafibranorum. Its PubChem CID is 9864881.
Elafibranor
| CAS No | 923978-27-2 |
|---|---|
| Molecular Formula | C22H24O4S |
| Molecular Weight | 384.5 g/mol |
| Synonyms | 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist that works to inhibit bile acid synthesis. On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).
The listed CAS number is 923978-27-2.
The listed molecular formula is C22H24O4S.
The listed molecular weight is 384.5 g/mol.
2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid.
The source lists Iqirvo and elafibranorum.